Big Sky Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2015
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Viruses and Human Cancer (D2)
Organizer(s) Charles R.M. Bangham, Thomas F. Schulz and Paul M. Lieberman
March 29—April 3, 2015
Big Sky Resort • Big Sky, MT USA
Discounted Abstract Deadline: Dec 2, 2014
Abstract Deadline: Jan 6, 2015
Scholarship Deadline: Dec 2, 2014
Discounted Registration Deadline: Jan 27, 2015
Sponsored by Merck & Co., Inc., Regeneron Pharmaceuticals, Inc. and Roche
Summary of Meeting:
In 1970, an authoritative book entitled “Viruses and Cancer” was published by Sir Christopher Andrews, one of the discoverers of influenza virus. On page 135 he wrote “Despite these findings, there is no doubt that as regards the generality of cancers in man, and indeed in other mammals, there is no direct evidence that viruses are concerned”. It is now estimated that about 20% of human cancers are caused by infectious agents, among them at least 7 viruses. The increasing appreciation of the role of viruses in cancer pathogenesis has not only already led to the development of two successful vaccines (against HBV and HPV) that prevent cancer, it has also directly contributed to many fundamental discoveries in cancer biology. In the last decade the understanding of virus-induced cancers has been accelerated by the extraordinary developments in genomics, epigenetics and RNA biology. To review this rapidly burgeoning field, this multidisciplinary symposium brings together experts in virology, oncology, immunology, genomics and genetics. The objective of the symposium is to explore how advances in cancer biology can inform the understanding of virus-induced cancers, and how viruses continue to reveal fundamental principles in cancer. Particular emphasis will be laid on the interaction between virus and host in persistent infections by oncogenic viruses. The meeting will cover examples of cancers where a viral cause is still under debate and the rapid development of technology for the detection of unknown viruses.
View Scholarships/Awards
In 1970, an authoritative book entitled “Viruses and Cancer” was published by Sir Christopher Andrews, one of the discoverers of influenza virus. On page 135 he wrote “Despite these findings, there is no doubt that as regards the generality of cancers in man, and indeed in other mammals, there is no direct evidence that viruses are concerned”. It is now estimated that about 20% of human cancers are caused by infectious agents, among them at least 7 viruses. The increasing appreciation of the role of viruses in cancer pathogenesis has not only already led to the development of two successful vaccines (against HBV and HPV) that prevent cancer, it has also directly contributed to many fundamental discoveries in cancer biology. In the last decade the understanding of virus-induced cancers has been accelerated by the extraordinary developments in genomics, epigenetics and RNA biology. To review this rapidly burgeoning field, this multidisciplinary symposium brings together experts in virology, oncology, immunology, genomics and genetics. The objective of the symposium is to explore how advances in cancer biology can inform the understanding of virus-induced cancers, and how viruses continue to reveal fundamental principles in cancer. Particular emphasis will be laid on the interaction between virus and host in persistent infections by oncogenic viruses. The meeting will cover examples of cancers where a viral cause is still under debate and the rapid development of technology for the detection of unknown viruses.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, MARCH 29
MONDAY, MARCH 30
TUESDAY, MARCH 31
WEDNESDAY, APRIL 1
THURSDAY, APRIL 2
FRIDAY, APRIL 3
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, MARCH 29
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—08:15
Welcome Remarks
Charles R.M. Bangham,
Imperial College Department of Medicine, UK
08:00—11:30
Mimicry of Host Pathways
*
Thomas F. Schulz,
Medizinische Hochschule Hannover, Germany
Carolina Arias,
University of California, Santa Barbara, USA
Cell Lineage Dramatically Impacts Kaposi’s Sarcoma-Associated Herpesvirus Gene Expression
Cell Lineage Dramatically Impacts Kaposi’s Sarcoma-Associated Herpesvirus Gene Expression
Blossom A. Damania,
University of North Carolina at Chapel Hill, USA
Subversion of Host Cell Signaling by KSHV
Subversion of Host Cell Signaling by KSHV
Ulrike Protzer,
Technische Universität München, Germany
Cytolytic and Non-Cytolytic Control of Hepatitis B Virus Persistence
Cytolytic and Non-Cytolytic Control of Hepatitis B Virus Persistence
Eleonora Forte,
Northwestern University, USA
Short Talk: A Partial Tumor Virus Mimic of miR-142-3p Disrupts Adherens Junctions
Short Talk: A Partial Tumor Virus Mimic of miR-142-3p Disrupts Adherens Junctions
Lori D. Frappier,
University of Toronto, Canada
Short Talk: Mechanism and Consequences of CK2 Kinase Hijacking by Epstein-Barr Virus Nuclear Antigen 1 (EBNA1)
Short Talk: Mechanism and Consequences of CK2 Kinase Hijacking by Epstein-Barr Virus Nuclear Antigen 1 (EBNA1)
14:30—16:30
Workshop 1: Viral Mimicry
*
Paul M. Lieberman,
Wistar Institute, USA
Silvia Gramolelli,
Hannover Medical School, Germany
Kaposi Sarcoma Herpesvirus (KSHV) K15 Protein Contributes to the Increased Invasiveness and Angiogenic Properties of Infected Endothelial Cells
Kaposi Sarcoma Herpesvirus (KSHV) K15 Protein Contributes to the Increased Invasiveness and Angiogenic Properties of Infected Endothelial Cells
Alexander S. Hahn,
University of Erlangen-Nuremberg, Germany
Rhadinovirus Receptor Tropism for Endothelial Cell Surface Molecules
Rhadinovirus Receptor Tropism for Endothelial Cell Surface Molecules
Christine Happel,
NCI, National Institutes of Health, USA
KSHV Regulation of the MicroRNA Biogenesis Pathway
KSHV Regulation of the MicroRNA Biogenesis Pathway
Robert F. Kalejta,
University of Wisconsin-Madison, USA
Retinoblastoma Protein Cleft and LxCxE Docking Motif Required for Human Cytomegalovirus vCdk UL97-Mediated Activation of E2F-Responsive Transcription
Retinoblastoma Protein Cleft and LxCxE Docking Motif Required for Human Cytomegalovirus vCdk UL97-Mediated Activation of E2F-Responsive Transcription
Frank Neipel,
Universitaet Erlangen, Germany
The Ephrin A2 Receptor Tyrosin Kinase (EphA2) Is Required for KSHV Endocytosis and Membrane Fusion in Endothelial Cells
The Ephrin A2 Receptor Tyrosin Kinase (EphA2) Is Required for KSHV Endocytosis and Membrane Fusion in Endothelial Cells
Vijay Kumar,
International Centre for Genetic Engineering and Biotechnology, India
HBx Oncoprotein Hijacks the Nucleolar Functions to Promote Cellular Transformation
HBx Oncoprotein Hijacks the Nucleolar Functions to Promote Cellular Transformation
17:00—19:15
Latency and Persistence I
*
Maria G. Masucci,
Karolinska Institute, Sweden
Alison A. McBride,
NIAID, National Institutes of Health, USA
Papillomaviruses exploit Multiple Cellular Processes to Replicate their Genomes at Different Phases of the Virus Life Cycle
Papillomaviruses exploit Multiple Cellular Processes to Replicate their Genomes at Different Phases of the Virus Life Cycle
David Thorley-Lawson,
Tufts University School of Medicine, USA
How EBV Persists in vivo and its Relevance to Human Cancer
How EBV Persists in vivo and its Relevance to Human Cancer
Paul M. Lieberman,
Wistar Institute, USA
Epigenetic Regulation of Gammaherpesvirus Latency
Epigenetic Regulation of Gammaherpesvirus Latency
Giuseppe Balistreri,
University of Helsinki, Finland
Short Talk: Stress Response and G2 Cell-Cycle Arrest during KSHV Lytic Phase Ensure Efficient Viral Lytic Gene Expression and Make Reactivated Cells Addicted to Anti-Apoptotic Pathways
Short Talk: Stress Response and G2 Cell-Cycle Arrest during KSHV Lytic Phase Ensure Efficient Viral Lytic Gene Expression and Make Reactivated Cells Addicted to Anti-Apoptotic Pathways
Jennifer Corcoran,
Dalhousie University, Canada
Short Talk: Viral Activation of MK2-hsp27-p115RhoGEF-RhoA Signaling Axis Causes Cytoskeletal Rearrangements, P-Body Disruption and ARE-mRNA Stabilization
Short Talk: Viral Activation of MK2-hsp27-p115RhoGEF-RhoA Signaling Axis Causes Cytoskeletal Rearrangements, P-Body Disruption and ARE-mRNA Stabilization
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Inflammation and Tumor Microenvironment
*
Ulrike Protzer,
Technische Universität München, Germany
Stacy M. Horner,
Duke University Medical Center, USA
Activation and Evasion of Innate Immune and Inflammatory Signaling by HCV
Activation and Evasion of Innate Immune and Inflammatory Signaling by HCV
Paivi M. Ojala,
Institute of Biotechnology, University of Helsinki, Finland
Lymphatic Reprogramming in KSHV Pathogenesis and Cancer
Lymphatic Reprogramming in KSHV Pathogenesis and Cancer
Benjamin E. Gewurz,
Brigham and Women's Hospital, Harvard Medical School, USA
Short Talk: The NF-kappaB Landscape in EBV-Transformed Lymphoblastoid B-Cells
Short Talk: The NF-kappaB Landscape in EBV-Transformed Lymphoblastoid B-Cells
Mei-Ru Chen,
National Taiwan University, Taiwan
Modification of Nuclear Envelope Induced by EBV Replication
Modification of Nuclear Envelope Induced by EBV Replication
Sang Hyuk Chung,
University of Houston, USA
Short Talk: Mechanisms by which Estrogen Receptor alpha Cooperates with HPV Oncogenes for Cervical Carcinogenesis
Short Talk: Mechanisms by which Estrogen Receptor alpha Cooperates with HPV Oncogenes for Cervical Carcinogenesis
Masaru Shimada,
Yokohama City University, Japan
Short Talk: The Role of Apoptosis Inducing Factor 1 (AIFM1) in HPV-Inducing Cancer
Short Talk: The Role of Apoptosis Inducing Factor 1 (AIFM1) in HPV-Inducing Cancer
17:00—19:30
Latency and Persistence II
*
Paul M. Lieberman,
Wistar Institute, USA
Charles R.M. Bangham,
Imperial College Department of Medicine, UK
Regulation of HTLV-1 Clonality: When Does Leukemia Result?
Regulation of HTLV-1 Clonality: When Does Leukemia Result?
Maria G. Masucci,
Karolinska Institute, Sweden
Disruption of Cellular Processes in Epstein-Barr Virus Replication and Oncogenesis
Disruption of Cellular Processes in Epstein-Barr Virus Replication and Oncogenesis
Thomas F. Schulz,
Medizinische Hochschule Hannover, Germany
BET Chromatin Proteins Regulate Gammaherpesviral Latency and Retroviral Integration
BET Chromatin Proteins Regulate Gammaherpesviral Latency and Retroviral Integration
Vaibhav Jain,
University of Florida, USA
Short Talk: Role of LANA N-Terminus Histone Binding Domain in Transcriptional Control and Episome Maintenance
Short Talk: Role of LANA N-Terminus Histone Binding Domain in Transcriptional Control and Episome Maintenance
19:30—20:30
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Genetics and Epigenetics I
*
Martin J. Allday,
Imperial College London, UK
Yorifumi Satou,
Kumamoto University, Japan
HTLV-1 Inserts an Ectopic CTCF-Binding Site into the Human Genome
HTLV-1 Inserts an Ectopic CTCF-Binding Site into the Human Genome
Lucas L. Willems,
Université de Liège, FNRS, Belgium
Mechanisms of BLV Persistence and Leukemogenesis
Mechanisms of BLV Persistence and Leukemogenesis
Paul F. Lambert,
University of Wisconsin, USA
What Drives Development of HPV-Associated Cancers?
What Drives Development of HPV-Associated Cancers?
Christine E. Birdwell,
Louisiana State University Health Sciences Center-Shreveport, USA
Short Talk: Epigenetic Consequences of Epstein-Barr Infection in Epithelial Cells
Short Talk: Epigenetic Consequences of Epstein-Barr Infection in Epithelial Cells
Sarah Jill de Jong,
Rockefeller University, USA
Short Talk: EV3 Deficiency - A New Genetic Etiology Predisposing to Severe beta-HPV Infection and Squamous Cell Carcinoma
Short Talk: EV3 Deficiency - A New Genetic Etiology Predisposing to Severe beta-HPV Infection and Squamous Cell Carcinoma
Massimo Tommasino,
Infections and Cancer Biology Group-IARC, France
Role of Viral Infections in Human Cancers
Role of Viral Infections in Human Cancers
14:30—16:30
Workshop 2: Innate Defense
*
Lucas L. Willems,
Université de Liège, FNRS, Belgium
Amy Y. Hafez,
Duke University, USA
EBV-Mediated B-Cell Transformation Is Suppressed by Oncogene-Induced Senescence through the DNA Damage Response
EBV-Mediated B-Cell Transformation Is Suppressed by Oncogene-Induced Senescence through the DNA Damage Response
Alexander M. Price,
Duke University, USA
Characterizing Survival in the Absence of LMP1-Mediated NF-kappaB Signaling Early after B-Cell Infection
Characterizing Survival in the Absence of LMP1-Mediated NF-kappaB Signaling Early after B-Cell Infection
Erica L. Sanchez,
University of Washington, USA
Latent KSHV Infected Endothelial Cells Are Glutamine Addicted and Require Glutaminolysis for Survival
Latent KSHV Infected Endothelial Cells Are Glutamine Addicted and Require Glutaminolysis for Survival
Guigen Zhang,
Hannover Medical School, Germany
Recruitment of an Innate Immune DNA Sensor by the Cytoplasmic Isoforms of KSHV LANA
Recruitment of an Innate Immune DNA Sensor by the Cytoplasmic Isoforms of KSHV LANA
Joseph M. Ziegelbauer,
NCI, National Institutes of Health, USA
KSHV MicroRNAs Target Growth Arrest and DNA Damage-Inducible Gene (GADD45B) and Protect Cells from DNA Damage Consequences
KSHV MicroRNAs Target Growth Arrest and DNA Damage-Inducible Gene (GADD45B) and Protect Cells from DNA Damage Consequences
Martin K. Thomsen,
Aarhus University, Denmark
The Innate DNA Sensing Pathway Is Not Operative in Hepatocytes: Impact on HBV Infection
The Innate DNA Sensing Pathway Is Not Operative in Hepatocytes: Impact on HBV Infection
14:30—16:30
Workshop 3: Virus Discovery and Therapy
*
W. Ian Lipkin,
Columbia University, USA
Johanna Classon,
Karolinska Institutet, Sweden
Human Cytomegalovirus and the Androgen Receptor in Prostate Cancer
Human Cytomegalovirus and the Androgen Receptor in Prostate Cancer
David Stein,
Oregon State University, USA
Inhibition of Primary Effusion Lymphoma in SCID Mice by Blocking the Expression of vIL-6 in an Oncogenic Virus
Inhibition of Primary Effusion Lymphoma in SCID Mice by Blocking the Expression of vIL-6 in an Oncogenic Virus
Jaap M. Middeldorp,
VU University Medical Center, Netherlands
Cytolytic Virus Activation Therapy for Epstein-Barr Virus Driven Tumors
Cytolytic Virus Activation Therapy for Epstein-Barr Virus Driven Tumors
J.J. Miranda,
Gladstone Institutes and University of California, San Francisco, USA
Viral Specificity of Small Molecule Latency Disruptors
Viral Specificity of Small Molecule Latency Disruptors
17:00—18:40
Genetics and Epigenetics II
*
Paul F. Lambert,
University of Wisconsin, USA
Martin J. Allday,
Imperial College London, UK
EBNA3 Proteins and the Modulation of Nuclear Processes during the Transformation of B Cells by EBV
EBNA3 Proteins and the Modulation of Nuclear Processes during the Transformation of B Cells by EBV
Matthew D. Weitzman,
Children's Hospital of Philadelphia, USA
Viral Manipulation of DNA Replication and Damage Responses
Viral Manipulation of DNA Replication and Damage Responses
Micah A. Luftig,
Duke University Medical Center, USA
Short Talk: A New Temporal Model for Epstein-Barr Virus Immortalization of Human B Cells
Short Talk: A New Temporal Model for Epstein-Barr Virus Immortalization of Human B Cells
Kayla Martin,
Temple University, USA
Short Talk: Epstein-Barr Virus Protein LMP1 Mediates Epigenetic-Driven Changes in Host and Viral Gene Expression through PARP1
Short Talk: Epstein-Barr Virus Protein LMP1 Mediates Epigenetic-Driven Changes in Host and Viral Gene Expression through PARP1
18:40—19:15
Immunity, Intracellular Defense and Vaccines
John T. Schiller,
NCI, National Institutes of Health, USA
Prophylactic HPV Vaccines: Why They Work So Well
Prophylactic HPV Vaccines: Why They Work So Well
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Host Defense
*
Charles R.M. Bangham,
Imperial College Department of Medicine, UK
Barbara Rehermann,
NIDDK, National Institutes of Health, USA
Host Responses to HCV: Inflammation and Innate Immune Cell Responses
Host Responses to HCV: Inflammation and Innate Immune Cell Responses
Adam J. Gehring,
St. Louis University School of Medicine, USA
Immunotherapy for Chronic HBV Infection and HBV-Related Liver Cancer: New Strategies to Exploit the Viral Life Cycle for Personalize Therapy
Immunotherapy for Chronic HBV Infection and HBV-Related Liver Cancer: New Strategies to Exploit the Viral Life Cycle for Personalize Therapy
Genoveffa Franchini,
NCI, National Institutes of Health, USA
Polymorphisms in the Orf-I Gene in HTLV-I Replication in Monocytes and Immune Evasion
Polymorphisms in the Orf-I Gene in HTLV-I Replication in Monocytes and Immune Evasion
Cliona M. Rooney,
Baylor College of Medicine, USA
Use of Viruses to Enhance the Efficacy of CAR-T-Cells
Use of Viruses to Enhance the Efficacy of CAR-T-Cells
Cécile Bauche,
Theravectys, France
Short Talk: Development of an Anti-HTLV-1 Vaccine for the Treatment of Adult T-Cell Leukemia/Lymphoma
Short Talk: Development of an Anti-HTLV-1 Vaccine for the Treatment of Adult T-Cell Leukemia/Lymphoma
Katja Spiess,
University of Copenhagen, Denmark
Short Talk: A Rationally Designed Chemokine-Based Toxin Targeting Human Cytomegalovirus Provides Efficient and Selective Killing of HCMV Infected Cells
Short Talk: A Rationally Designed Chemokine-Based Toxin Targeting Human Cytomegalovirus Provides Efficient and Selective Killing of HCMV Infected Cells
17:00—19:00
Genomics and Virus Discovery
*
Ruth F. Jarrett,
University of Glasgow, UK
Patrick S. Moore,
University of Pittsburgh Cancer Institute, USA
How to Find a New Human Virus: Lessons from Merkel Cell Polyomavirus and Kaposi's Sarcoma Herpesvirus
How to Find a New Human Virus: Lessons from Merkel Cell Polyomavirus and Kaposi's Sarcoma Herpesvirus
Anne Palser,
Wellcome Trust Sanger Institute, UK
EBV Sequencing Data
EBV Sequencing Data
Aaron J. Arvey,
Gilead, USA
Short Talk: Host and Viral Transcriptome Landscape of AIDS-Related Lymphomas
Short Talk: Host and Viral Transcriptome Landscape of AIDS-Related Lymphomas
19:15—20:15
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
